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Abstract
Background: Hypertension and type 2 diabetes are common co-morbidities. Preliminary studies
suggest that thiazolidinediones reduce blood pressure (BP). We therefore used ambulatory BP to
quantify BP lowering at 6–12 months with rosiglitazone used in combination with metformin or
sulfonylureas compared to metformin and sulfonylureas in people with type 2 diabetes.
Methods: Participants (n = 759) in the multicentre RECORD study were studied. Those taking
metformin were randomized (open label) to add-on rosiglitazone or sulfonylureas, and those on
sulfonylurea to add-on rosiglitazone or metformin.
Results: 24-Hour ambulatory BP was measured at baseline, 6 months and 12 months. At 6 and 12
months, reductions in 24-hour ambulatory systolic BP (sBP) were greater with rosiglitazone versus
metformin (difference at 6 months 2.7 [95% CI 0.5–4.9] mmHg, p = 0.015; 12 months 2.5 [95% CI
0.2–4.8] mmHg, p = 0.031). Corresponding changes for ambulatory diastolic BP (dBP) were
comparable (6 months 2.7 [95% CI 1.4–4.0] mmHg, p < 0.001; 12 months 3.1 [95% CI 1.8–4.5]
mmHg, p < 0.001). Similar differences were observed for rosiglitazone versus sulfonylureas at 12
months (sBP 2.7 [95% CI 0.5–4.9] mmHg, p = 0.016; dBP 2.1 [95% CI 0.7–3.4] mmHg, p = 0.003),
but differences were smaller and/or not statistically significant at 6 months (sBP 1.5 [95% CI -0.6 to
3.6] mmHg, p = NS; dBP 1.3 [95% CI 0.0–2.5] mmHg, p = 0.049). Changes in BP were not
accompanied by compensatory increases in heart rate, did not correlate with basal insulin
sensitivity estimates and were not explained by changes in antihypertensive therapy between the
various strata.
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Conclusion: When added to metformin or a sulfonylurea, 12-month treatment with rosiglitazone
reduces ambulatory BP to a greater extent than when metformin and a sulfonylurea are combined.
Trial registration: NCT00379769 http://clinicaltrials.gov/
Background
Cardiovascular disease accounts for the majority of mor-
tality and morbidity associated with type 2 diabetes [1-3].
Elevated blood pressure (BP) is a major cardiovascular
risk factor in type 2 diabetes. Lowering BP has been shown
to reduce the risk of cardiovascular complications in these
people [4-7], and is particularly important in diabetes care
due to the prevention of retinopathy and nephropathy
[4,8,9]. Thus, BP reduction is both clinically and econom-
ically more effective in people with diabetes [10], and
guidelines now recommend lower BP treatment thresh-
olds and targets than for non-diabetic people [5-7,11].
Rosiglitazone is a PPAR-γ (peroxisome proliferator-acti-
vated receptor-gamma) agonist that has been shown to
improve insulin sensitivity, resulting in improved glycae-
mic control in people with type 2 diabetes [12-14]. Thia-
zolidinediones have been shown to exert beneficial effects
on inflammation or coagulation markers and on lipopro-
tein profile in vivo [15-17]. Moreover, it was observed
recently that a thiazolidinedione slowed the progression
of carotid intima-media thickness, a validated surrogate
marker of atherosclerosis and cardiovascular risk, when
compared with glimepiride in type 2 diabetic patients
[18]. Finally, these compounds have also been reported to
lower BP in animal models [19], people with impaired
glucose tolerance [20], people with type 2 diabetes with
and without hypertension [21-27] and non-diabetic
hypertensives [28]. However, these BP studies have signif-
icant limitations, being uncontrolled observations
[25,26,28] of small sample size [20,21,23-28] and/or
short treatment duration [20,23-25,27,28].
There was thus a need for a large, adequate duration, pro-
spectively defined and actively controlled study from
which the effect of rosiglitazone on BP could be ade-
quately assessed. RECORD (Rosiglitazone Evaluated for
Cardiac Outcomes and Regulation of glycaemia in Diabe-
tes), a study of combination oral therapies, was a useful
environment in which to do this, the design allowing
comparison of rosiglitazone against both metformin and
sulfonylureas [29]. Ambulatory BP measurement
(ABPM), while too cumbersome to apply in every centre
participating in the RECORD study, offered the chance of
more accurate and precise assessments than performed
previously. The present paper therefore reports the results
of 12-month ABPM conducted as a prospectively designed
study of a subset of participants within the RECORD trial
[29].
Methods
The design of the RECORD study has been described in
detail elsewhere [29].
Participants
RECORD involves 330 study centres in 23 countries in
Europe and Australasia. People with type 2 diabetes (n =
4458) inadequately controlled on metformin or sulfony-
lurea monotherapy were enrolled. The pre-specified 12-
month ABPM study was conducted at 128 centres in 16
countries in Europe. At these centres, people were invited
to participate in the ABPM study at the time of enrolment
into the main study. Enrolment continued until target
entry numbers with a valid baseline ABPM record were
reached in each group. Eligible participants had type 2
diabetes as defined by the 1999 World Health Organiza-
tion criteria [30], were aged 40–75 years, with a body
mass index of > 25.0 kg/m2 and HbA1c 7.1–9.0%, on max-
imum permitted or tolerated doses of metformin or a sul-
fonylurea (glibenclamide [glyburide], glimepiride or
gliclazide) at study entry. Individuals were not to be
included if their clinic BP was > 180/105 mmHg.
The ABPM study protocol was approved by ethics review
according to local laws/customs and was carried out in
accordance with the Declaration of Helsinki. Written
informed consent was obtained before beginning any pro-
tocol-specific procedure.
Study design
This study is a multicentre, randomized, open-label, com-
parative, parallel-group trial [29]. Eligible participants
continued to take their current glucose-lowering drug
(metformin or sulfonylurea) and entered a 4-week run-in
period of reinforcement of lifestyle education, followed
by concealed randomization. Treatment allocation was
stratified for current glucose-lowering medication. Those
taking a sulfonylurea were randomized to additional ros-
iglitazone or metformin, and those taking metformin to
additional rosiglitazone or a sulfonylurea (glibenclamide,
gliclazide or glimepiride, according to local practice).
Throughout the study, participants were treated to a target
HbA1c of ≤ 7.0%. If HbA1c rose above 7.0% at any point
after 8 weeks of randomized treatment, the dose of the
study medication was increased to a maximum of 4 mg
rosiglitazone twice daily, 2550 mg/day metformin, 15
mg/day glibenclamide (or equivalent), 240 mg/day gli-
clazide or 4 mg/day glimepiride. If HbA1c was ≥ 8.5%
(confirmed) on the maximum tolerated dose for at least 8
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weeks, a third glucose-lowering agent was added and their
data censored from that point onwards.
Any antihypertensive medication in use before randomi-
zation could be continued during the study. For partici-
pants whose BP was subsequently judged by their
physician to require additional medication, it was recom-
mended to modify treatment in accordance with the IDF
Type 2 Diabetes European Policy Group guidelines [31].
Ambulatory blood pressure monitoring
Ambulatory BP was measured using a Spacelabs 90207
device (Spacelabs, Redmond, WA, USA) during the week
prior to randomization and at 6 and 12 months [32]. The
device recorded diastolic and systolic BP (dBP and sBP)
and heart rate every 20 minutes from 08:00 to 22:00 h
('day-time') and every hour from 22:00 to 08:00 h ('night-
time'), such that approximately 52 readings were taken
during the 24-hour assessment. Weighted mean 24-hour,
daytime and night-time BP and heart rate were calculated.
To be used for the analysis, the 24-hour ABPM had to span
a minimum of 24 hours, and have no more than two non-
consecutive day-time hours with fewer than two valid
readings, and no more than two non-consecutive night-
time hours with no valid readings. The validity of record-
ings was determined by a third party (Biomedical Sys-
tems, Brussels, Belgium), blind to treatment allocation.
Insulin sensitivity, body weight and adverse events
Homeostasis model assessment estimates of insulin sensi-
tivity (HOMA%S) were calculated using the HOMA Cal-
culator (version 2.2; Oxford Trials Unit, Oxford, UK) [33].
The inputs to the HOMA model, fasting plasma glucose
and serum insulin were assayed at a central laboratory
(Quest Diagnostics, Heston, UK) as previously described
[29]. Body weight was assessed at baseline and all six fol-
low-up visits.
Although the RECORD study is ongoing to 2008, some
preliminary efficacy and safety-related data (including
fluid retention) were published urgently in 2007, follow-
ing publication of a meta-analysis of some rosiglitazone
studies [34,35]. Some other outcome data for rosiglita-
zone have become available at FDA Advisory Committee
hearings. However, a full safety analysis from RECORD
will await study completion [36].
Statistical analysis
The primary efficacy measure for this ABPM sub-study was
the change from baseline in 24-hour ambulatory dBP after
6 months between rosiglitazone and comparator in the
two background therapy groups. Hence, only those with a
valid ambulatory baseline assessment are considered. A
sample size of 141 participants per treatment group (564
in total) was estimated to give an 80% power of detecting
a 2 mmHg difference in dBP between treatment groups,
assuming a standard deviation of 6 mmHg for the change
from baseline and a two-sided alpha = 0.05.
Changes from baseline in mean 24-hour, day- and night-
time ambulatory dBP and sBP, and heart rate were ana-
lysed using repeated measures at 6 and 12 months for the
modified intent-to-treat (ITT) population (all rand-
omized, treated and with at least one data point post-ran-
domization). The model included terms for age, gender,
presence of hypertension, treatment and baseline by visit
interaction, and employed an unstructured covariance
matrix to model the within-patient variability for each
treatment group. Presence of hypertension was taken as
average baseline daytime ABPM > 135/85 mmHg or prior
diagnosis of hypertension. No adjustment was made for
the confounding effects due to new antihypertensive med-
ication during follow-up, as this cannot be done reliably.
Antihypertensive medication use (number of agents and
class) was summarized at baseline and at end of follow-up
in all treatment groups. In order to take into account
changes occurring in antihypertensive therapy, the time-
course for first introducing new/increased antihyperten-
sive medication was estimated using the Kaplan-Meier
method, and treatment groups compared using Log rank
tests.
To assess the day-night interaction, the differences (day-
night) for dBP and sBP, and heart rate were analysed using
the same methodology as for other BP measures. This
methodology was also used for analyses of body weight.
The relationship between changes from baseline in BP
and each of log-transformed HOMA%S and body weight
by 12 months was explored by scatter plots and correla-
tion coefficients (Pearson and Spearman rank). All analy-
ses were adjusted for baseline measurements to correct for
any baseline imbalances between treatment groups. All
significance tests and confidence intervals were two sided
and performed or constructed at the 5% significance level.
Analyses were conducted using SAS for Windows (version
8.2; SAS Institute, Cary, NC, USA).
Results
A total of 926 people were randomized (ABPM study), of
whom 759 had a valid baseline ABPM profile. Of these,
668 had at least one valid post-randomization ABPM pro-
file (545 at both 6 and 12 months, 88 at 6 months only,
35 at 12 months only), forming the modified ITT popula-
tion. Baseline characteristics are given in Table 1.
Approximately half of the participants were male and all
but one was Europid. Within stratum the randomized
groups were well matched, but the background met-
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formin stratum was younger, more overweight and had
shorter duration of diabetes than the sulfonylurea stra-
tum. The presence of microalbuminuria at baseline was
low in all four treatment groups. Eighty-four percent of
participants had hypertension at baseline, already diag-
nosed (73%) or identified by the baseline ABPM (11%).
Antihypertensive medication was being taken at baseline
by 449 (67%) participants (single agent 207 participants
[31%], two drugs 159 [24%], three or more drugs 83
[12%]). The distribution of class of antihypertensive treat-
ment and number of agents was very similar in all four
treatment groups (Table 2).
After 12 months, 96% of the participants in the modified
ITT population were continuing to take their allocated
dual oral glucose-lowering therapy. More participants in
the metformin+rosiglitazone and sulfonylurea+rosiglita-
zone groups ceased dual combination treatment (8% and
5%, respectively) than in non-rosiglitazone groups (< 1%
for both), the majority by progression to triple therapy
(6% and 4%, respectively).
Changes in antihypertensive medication at end of follow-
up were similar in all groups (Table 2). Antihypertensive
medication was started in the background metformin stra-
tum in 27 (8%) participants (rosiglitazone 13; sulfonylu-
rea 14), additional drugs were taken by 55 (16%)
(rosiglitazone 31; sulfonylurea 24), and an increased dose
in 18 (5%) (rosiglitazone 9; sulfonylurea 9). The same
matched intensification was observed in the background
sulfonylurea stratum: 24 participants (7%) started treat-
ment (rosiglitazone 15; metformin 9), 39 (12%) added a
new drug (rosiglitazone 19; metformin 20), and 15 (5%)
increased the dose (rosiglitazone 7; metformin 8).
The time-course for first introducing new/increased anti-
hypertensive medication during follow-up was similar for
rosiglitazone-treated patients and the respective control
groups (Log rank test p-value both > 0.50). Kaplan-Meier
estimates of the proportion who introduced new/
increased antihypertensive medication by 12 months
were 30.1% (95% CI 23.2–37.0) and 28.7% (95% CI
21.6–35.7) of the background metformin participants on
rosiglitazone and sulfonylurea, respectively, and 26.4%
(95% CI 19.3–33.5) and 21.5% (95% CI 14.8–28.2) of
background sulfonylurea participants using rosiglitazone
and metformin, respectively.
Table 1: Clinical characteristics of the population studied
Background metformin Background sulfonylurea
+ rosiglitazone + sulfonylurea + rosiglitazone + metformin
Participants (n) 176 165 160 167
Age (yr) 57 ± 8 57 ± 8 60 ± 8 58 ± 8
Male (n (%)) 80 (45) 86 (52) 83 (52) 77 (46)
Europid (n (%)) 175 (> 99) 165 (100) 160 (100) 167 (100)
Body weight (kg) 92 ± 17 94 ± 16 86 ± 13 84 ± 16
BMI (kg/m2) 33 ± 5 32 ± 5 31 ± 4 30 ± 5
Time from diabetes diagnosis (yr) 5.7 ± 3.8 5.9 ± 3.6 7.7 ± 5.1 7.1 ± 5.1
HbA1c (%) 7.8 ± 0.6 7.8 ± 0.8 7.9 ± 0.7 8.0 ± 0.8
Fasting plasma glucose (mmol/l) 9.2 ± 2.1 9.7 ± 2.3 10.0 ± 2.4 10.2 ± 2.4
Homeostasis model assessment %S (%) 68 (42, 106) 64 (42, 108) 64 (47, 88) 63 (42, 93)
Hypertension* (n (%)) 145 (82) 138 (84) 139 (87) 141 (84)
Treated with antihypertensive drugs 119 (68) 112 (68) 104 (65) 114 (68)
Ambulatory systolic BP (mmHg)
24-hour 132 ± 14 134 ± 16 132 ± 13 132 ± 14
Day-time 136 ± 14 138 ± 15 135 ± 13 136 ± 14
Night-time 126 ± 15 128 ± 18 126 ± 14 127 ± 15
Ambulatory diastolic BP (mmHg)
24-hour 78 ± 8 78 ± 9 76 ± 8 76 ± 8
Day-time 81 ± 8 82 ± 10 79 ± 8 79 ± 8
Night-time 72 ± 9 73 ± 10 71 ± 9 71 ± 9
Ambulatory heart rate (beat/min)
24-hour 76 ± 10 75 ± 9 74 ± 11 75 ± 10
Day-time 81 ± 11 80 ± 10 79 ± 12 78 ± 11
Night-time 70 ± 9 69 ± 9 68 ± 10 69 ± 9
Number (percent) or mean ± SD, or median (IQR).
*Medical history or average baseline day-time ABPM > 135/85 mmHg
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24-hour ambulatory blood pressure
The majority of participants had at least 85% of valid
readings during the 24-hour ABPM assessment. For rosigl-
itazone added to background sulfonylurea, the reduction
in 24-hour sBP was significantly greater at both 6 (-3.8
mmHg) and 12 (-3.8 mmHg) months than with met-
formin added to sulfonylurea (-1.2 and -1.3 mmHg) (6
months, p = 0.015; 12 months, p = 0.031) (Figure 1 and
Table 3). Reductions in 24-hour dBP were also statistically
significantly greater at both 6 and 12 months with rosigl-
itazone added to sulfonylurea (-3.1 and -3.7 mmHg) than
with metformin added to sulfonylurea (-0.4 and -0.6
mmHg; both p < 0.001).
At 12 months, the reduction in 24-hour sBP was signifi-
cantly greater (p = 0.016) for rosiglitazone added to met-
formin (-4.9 mmHg) than for sulfonylurea added to
metformin (-2.2 mmHg) (Figure 1 and Table 3). Diastolic
BP at 12 months was also reduced to a greater extent by
rosiglitazone added to metformin (-3.8 mmHg) than by
sulfonylurea added to metformin (-1.7 mmHg; p =
0.003). At 6 months, both for sBP and dBP, the changes
Table 2: Blood pressure lowering medication at baseline and end of follow-up
Background metformin Background sulfonylurea
+ rosiglitazone + sulfonylurea + rosiglitazone + metformin
Modified ITT population (n) 176 165 160 167
Type of medication (n (%))
Baseline
Any BP medication 119 (68) 112 (68) 104 (65) 114 (68)
ACEi/ARB 91 (52) 83 (50) 80 (50) 88 (53)
β-blocker 44 (25) 42 (25) 34 (21) 43 (26)
CCB 37 (21) 33 (20) 28 (17) 36 (22)
Diuretics 28 (16) 34 (21) 26 (16) 38 (23)
End of follow-up*
Any BP medication 131 (74) 124 (75) 119 (74) 121 (72)
ACEi/ARB 99 (56) 93 (56) 89 (56) 92 (55)
β-blocker 51 (29) 53 (32) 40 (25) 46 (27)
CCB 47 (27) 39 (24) 32 (20) 40 (24)
Diuretics 48 (27) 39 (24) 34 (21) 41 (25)
Number of drug classes (n (%))
Baseline
0 57 (32) 53 (32) 56 (35) 53 (32)
1 62 (35) 47 (28) 51 (32) 47 (28)
2 34 (19) 45 (27) 37 (23) 43 (26)
3 17 (10) 15 (9) 14 (9) 20 (12)
> 3 6 (3) 5 (3) 2 (1) 4 (2)
End of follow-up
0 45 (25) 41 (25) 41 (26) 46 (27)
1 57 (32) 47 (28) 58 (36) 45 (27)
2 34 (19) 47 (28) 41 (26) 50 (30)
3 27 (15) 22 (13) 15 (9) 19 (11)
> 3 13 (7) 8 (5) 5 (3) 7 (4)
Data are n or n (%).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
*End of follow-up refers to time of stopping dual combination therapy or 12 months, whichever is sooner
Model-adjusted mean difference in ABPM for rosiglitazone compared to sulfonylurea and to metformin in combination therapyFigure 1
Model-adjusted mean difference in ABPM for rosigli-
tazone compared to sulfonylurea and to metformin 
in combination therapy.
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from baseline and difference between the treatment
groups were less pronounced (sBP, p = NS; dBP, p =
0.049).
Data analysis for the sub-population with hypertension at
baseline (84% of the study population) gave very similar
results to those of the whole population (data not
shown).
No sizeable correlation was found at 12 months between
change in 24-hour ABPM and change in HOMA%S in any
of the rosiglitazone treatment groups (r= -0.03 to -0.20)
(data not shown). In addition, no sizeable correlation was
found at 12 months between change in 24-hour ABPM
and body weight change (r= -0.14 to 0.16; data not
shown).
Similar increases in body weight from baseline to 12
months were observed in both arms of the metformin
stratum (rosiglitazone: +1.9 kg [95% CI 1.3–2.6]; sulfony-
lurea: +1.5 kg [95% CI 1.0–2.1]; difference: 0.4, p = NS).
In the sulfonylurea stratum there was a significant
increase in body weight with rosiglitazone compared to a
slight decrease with metformin (rosiglitazone: +2.2 kg
[95% CI 1.6–2.7]; metformin: -1.1 kg [95% CI -1.5 to -
0.6]; difference: 3.3, p < 0.0001).
Diurnal blood pressure contrasts
In general, the day- and night-time analyses were consist-
ent with the 24-hour findings, with all the BP reductions
on rosiglitazone at 12 months numerically greater than
for comparator metformin and sulfonylurea arms, and in
the majority of these sub-analyses statistically significant
(Table 4).
For each contrast, the confidence intervals of the day- and
night-time differences overlap. However, the effects of ros-
iglitazone compared with metformin tended to be larger
during the night than during the day (day-night differ-
ence: sBP, p = 0.018; dBP, p = 0.020), while the effects
compared to sulfonylurea tended to be larger or no differ-
ent during the day (sBP, p = 0.052; dBP, p = NS).
Table 3: Change from baseline in 24-h ambulatory BP and heart rate at 6 and 12 months
Background metformin Background sulfonylurea
+ rosiglitazone 
(n = 176)
+ sulfonylurea 
(n = 165)
difference (95% CI),
 p-value
+ rosiglitazone 
(n = 160)
+ metformin 
(n = 167)
difference (95% CI), 
p-value
ystolic BP change (mmHg)
6 months -3.1 (-4.8, -1.4) -1.6 (-3.5, + 0.3) -1.5 (-3.6, 0.6), NS -3.8 (-5.8, -1.8) -1.2 (-3.0, + 0.7) -2.7 (-4.9, -0.5), 0.015
12 months -4.9 (-6.7, -3.2) -2.2 (-4.2, -0.3) -2.7 (-4.9, -0.5), 
0.016
-3.8 (-5.9, -1.8) -1.3 (-3.3, + 0.7) -2.5 (-4.8, -0.2), 0.031
Diastolic BP change (mmHg)
6 months -2.8 (-3.8, -1.9) -1.6 (-2.7, -0.5) -1.3 (-2.5, -0.0), 
0.049
-3.1 (-4.2, -2.0) -0.4 (-1.6, + 0.7) -2.7 (-4.0, -1.4), < 0.001
12 months -3.8 (-4.9, -2.7) -1.7 (-2.9, -0.5) -2.1 (-3.4, -0.7), 
0.003
-3.7 (-4.9, -2.5) -0.6 (-1.7, + 0.6) -3.1 (-4.5, -1.8), < 0.001
Heart rate change (beat/min)
6 months -0.4 (-1.6, + 0.8) -0.1 (-1.3, + 1.0) -0.3 (-1.7, 1.1), NS -0.7 (-1.9, + 0.5) 1.3 (+ 0.1, + 2.6) -2.0 (-3.4, -0.6), 0.006
12 months -0.9 (-2.2, + 0.4) 0.0 (-1.3, + 1.3) -0.9 (-2.5, 0.7), NS -0.9 (-2.3, + 0.5) 1.7 (+ 0.3, + 3.1) -2.6 (-4.2, -1.0), 0.002
Modified ITT population; data are model-adjusted mean (95% CI), or number
Table 4: Contrast between day- and night-time effects of rosiglitazone on ambulatory BP at 12 months
Background metformin Background sulfonylurea
rosiglitazone vs sulfonylurea (difference (95% CI), p-value) rosiglitazone vs metformin (difference (95% CI), p-value)
Systolic BP (mmHg)
24-hour -2.7 (-4.9, -0.5), 0.016 -2.5 (-4.8, -0.2), 0.031
Day-time -3.3 (-5.6, -1.0), 0.004 -1.6 (-3.9, 0.9), NS
Night-time -1.5 (-3.9, 1.0), NS -4.0 (-6.6, -1.3), 0.004
Diastolic BP (mmHg)
24-hour -2.1 (-3.4, -0.7), 0.003 -3.1 (-4.5, -1.8), < 0.001
Day-time -2.5 (-3.9, -1.0), 0.001 -2.5 (-3.9, -1.0), 0.001
Night-time -1.3 (-2.9, 0.3), NS -4.0 (-5.7, -2.4), < 0.001
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The day-night profiles at 6 months were similar to those
observed at 12 months (data not shown).
Ambulatory heart rate
The greater reductions in BP in the rosiglitazone groups
were not accompanied by a compensatory increase in
ambulatory heart rate (Table 3). Heart rate did increase in
the group in which metformin was added to sulfonylurea,
such that adjusted heart rate changes from baseline at 6
and 12 months were statistically significantly lower with
rosiglitazone (Table 3).
Discussion
Blood pressure lowering effect of rosiglitazone
The study was designed to provide the first large, adequate
duration, prospectively defined and controlled trial in
which the effect of rosiglitazone on BP profile in people
with type 2 diabetes could be accurately determined.
Some long-term data are available for pioglitazone,
another PPAR-γ agonist, but those data were not actively
controlled, are based on clinic measurements and were
gained in a sub-population of people with overt cardio-
vascular disease [37].
Our primary finding was that rosiglitazone added to
either metformin or to a sulfonylurea reduced ambulatory
sBP and dBP and this effect was greater than that observed
with the standard diabetes combination treatment of met-
formin and a sulfonylurea. The magnitude of the reduc-
tions in BP is consistent with that reported in previous
smaller, uncontrolled or shorter duration studies [20-28].
The reductions are smaller than those achieved with
main-line antihypertensive agents but, importantly, were
achieved in a population already receiving appropriate
care for BP management, and therefore not markedly
hypertensive. The changes in antihypertensive therapy
(number of agents and dosage) and time-course for first
introducing new/increased therapy during follow-up were
similar for rosiglitazone-treated patients and respective
control groups, and are therefore unlikely to have caused
bias or explain the findings.
Rosiglitazone reduced sBP and dBP compared with active
controls in both day- and night-time periods in most, but
not all, of the treatment comparisons, with an inconsist-
ent pattern by background therapy (added to metformin
or sulfonylurea). This suggests that, while the sample size
proved sufficient to investigate the 24-hour measurement,
there was insufficient power to interrogate effects com-
pletely reliably when the data were divided between day
and night. Nevertheless, the observed data portray a
greater effect of rosiglitazone versus metformin during the
night and a greater effect versus sulfonylurea during the
day. This finding should be taken as observational and
needs confirmation.
Potential mechanism of the effect on blood pressure
The mechanism by which rosiglitazone reduces BP
remains unclear.
1) Previous small studies have reported an association
between reductions in BP seen with rosiglitazone and its
effects on insulin sensitivity measured by euglycaemic-
hyperinsulinaemic clamp [28] or estimated by HOMA
[21,26]. However, the lack of correlation between changes
in HOMA-estimated insulin sensitivity and ambulatory
BP changes in this much larger sample suggests that the
mechanisms by which rosiglitazone exerts these two
effects are likely to be independent of each other. This lack
of correlation is in line with the fact that some beneficial
effects of thiazolidinediones on inflammation or athero-
sclerosis markers have been shown to be independent
from blood glucose control and attributed to PPAR-γ [38].
2) Improvement in endothelial function might be a con-
tributor to BP reduction since improvements in endothe-
lial function have been attributed to rosiglitazone as
determined by improvements in forearm blood flow
[23,39], reductions in asymmetric dimethylarginine con-
centrations [40] and improved arterial function and elas-
ticity [41].
3) A direct vascular effect of thiazolidinediones has been
demonstrated in vascular smooth muscle in vitro through
a blockade of calcium uptake. This inhibition of inward
Ca2+ current through L-type channels in vascular smooth
muscle might result in a BP-lowering effect through a
vasodilatory effect [42-44]. Since arterial tone is influ-
enced by the activation of calcium-dependent potassium
channels in several vascular beds, the blocking effect of
sulfonylurea agents such as glibenclamide on these chan-
nels might result in a vasoconstrictive effect, leading to
increased BP [45]. We indeed observed a greater BP-low-
ering effect when rosiglitazone was added to sulfonylurea
than when it was added to metformin.
4) Reductions in insulin resistance at the endothelial cell
level, leading to an improvement in endothelial function,
could be postulated as a contributor to the BP reduction,
even if it now seems unlikely to be related to a whole body
effect on insulin sensitivity. One such mechanism might
be through antioxidant properties [46].
5) Other potential mechanisms that have been explored
include a down regulation of sympathetic nerve activity
[27] and effects secondary to the decrease in plasma non-
esterified fatty acids or to the increase in insulin sensitiv-
ity. Rosiglitazone has also been shown to down regulate
the renin-angiotensin system in human subcutaneous
adipose tissue [47] and it has been proposed that this
effect may contribute to its BP-lowering activity. The BP
Cardiovascular Diabetology 2008, 7:10 http://www.cardiab.com/content/7/1/10
Page 8 of 10
(page number not for citation purposes)
lowering was observed without significant increase in
heart rate, suggesting that a vasodilatory effect is not the
predominant mechanism.
Potential implication for cardiovascular risk
Prospective observational studies, such as that performed
within the UK Prospective Diabetes Study [48], suggest
that in people with type 2 diabetes there was a linear rela-
tionship with no threshold between BP reduction and car-
diovascular risk, and have thus concluded that any
reduction of raised BP is likely to have benefit. The
observed reductions in sBP and dBP were in the range of
2–3 mmHg. Such a reduction in BP has been observed in
several large BP trials comparing active treatments and
placebo, or aggressive versus less aggressive strategies, and
was associated with a significant improvement in cardio-
vascular outcome [49,50]. To what extent changes in BP
with thiazolidinediones translate into a significant
decrease in cardiovascular risk remains unclear. In a report
to an FDA Advisory Committee, the manufacturer of ros-
iglitazone reported a significant decrease in stroke for
integrated analysis of early short-term trials (HR 0.48
[0.23–0.98]) and a non-significant change for the
RECORD interim analysis (HR 0.76 [0.47–1.23]) [36].
It is noteworthy that in a study using carotid intima-media
thickness, a recognized surrogate marker for cardiovascu-
lar risk, the effect of pioglitazone seemed numerically
greater (although not significant statistically) in the sub-
group of patients with higher BP levels at baseline [18].
The number of cardiovascular events was limited in this
study owing to the size and duration of the study, but was
smaller in the thiazolidinedione arm.
In a large outcome trial of more than 5000 patients with
type 2 diabetes and evidence of macrovascular disease,
pioglitazone did not significantly reduce the composite
primary end point but did significantly reduce the risk of
the main secondary end point, including all-cause mortal-
ity, myocardial infarction or stroke, and also reduced the
recurrence of myocardial infarction in the subgroup of
patients with previous myocardial infarction [37,51].
A recent meta-analysis including 42 trials, many of which
were short term, suggested that rosiglitazone was associ-
ated with a significant increase in the risk of myocardial
infarction [34]. These results were, however, not con-
firmed by the interim analysis of the major cardiovascular
events occurring in the RECORD trial [35]. This analysis,
after 3.75 years of follow-up, was inconclusive regarding
the effect of rosiglitazone on the risk of death or hospital-
ization from cardiovascular causes and was insufficient to
determine whether the drug was associated with an
increase in the risk of myocardial infarction. Observa-
tional studies have also shown conflicting results [52,53].
Overall, these results indicate that the impact of thiazoli-
dinediones and particularly of rosiglitazone on cardiovas-
cular outcome is unclear.
Combination oral-agent therapy to achieve guideline-
advocated targets for blood glucose control is becoming
commonplace. The setting for the present study, in which
rosiglitazone is being used as part of a combination treat-
ment regimen, thus has the advantage of being particu-
larly clinically relevant. The patient demography and
baseline assessments were very similar in this sub-study
group and the total RECORD population of 4458 individ-
uals [29], suggesting that the selection of sites and enrol-
ment by specific invitation for the ABPM study did not
lead to a subgroup which was unrepresentative of the
study as a whole. Other strengths of this study include its
large population, 12-month treatment duration, use of
24-hour ambulatory BP assessment (as opposed to sitting
office measurements) and the consistency of the rosiglita-
zone effects in the two background treatment strata. Both
the glucose-lowering study drugs and background antihy-
pertensive drugs were used in line with prevailing clinical
practice without the artificial restrictions that characterize
many clinical trials.
Limitations
However, the study does have a number of weaknesses.
This was an open-label study, which could have under-
mined the concealed randomization if appreciable num-
bers of participants had withdrawn after being told to
which treatment group they had been allocated. However,
only one subject withdrew after randomization before
starting treatment. In order to reduce the potential for bias
on the primary end point, the decision on the validity of
all ambulatory BP readings was made observer blind by
an independent third party. Another potential limitation
was that background antihypertensive therapies could be
modified during the study, but increases in dose and addi-
tion of new agents and the time course of these events
were well balanced across all study treatment groups. The
treatment algorithm for managing unacceptably high lev-
els of glucose control was by necessity asymmetrical and
thus ambulatory BP assessments were censored after these
transitions from dual oral therapy. In the early stages of
the study, more patients stopped dual oral therapy in the
rosiglitazone-containing arms than those on metformin
plus sulfonylurea, which might have introduced a patient
or physician preference bias given the open-label nature
of the study. However, the absolute numbers involved
were small.
Conclusion
This sub-study has demonstrated that rosiglitazone,
added to either metformin or to a sulfonylurea, reduces
ambulatory BP and that this effect, following 12-month
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treatment, is greater than that observed with the standard
glucose-lowering combination of metformin and a sulfo-
nylurea. Whether the reduction in BP observed with this
compound translates into improved cardiovascular out-
come needs further evaluation.
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